"Ifosfamide" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Positional isomer of CYCLOPHOSPHAMIDE which is active as an alkylating agent and an immunosuppressive agent.
| Descriptor ID |
D007069
|
| MeSH Number(s) |
D02.455.526.728.650.730.243.250 D02.705.672.500.243.250 D03.383.533.500
|
| Concept/Terms |
Ifosfamide- Ifosfamide
- Isofosfamide
- Isophosphamide
- Iphosphamide
- Iso-Endoxan
- Iso Endoxan
NSC-109,724- NSC-109,724
- NSC 109,724
- NSC109,724
- NSC-109724
- NSC 109724
- NSC109724
|
Below are MeSH descriptors whose meaning is more general than "Ifosfamide".
Below are MeSH descriptors whose meaning is more specific than "Ifosfamide".
This graph shows the total number of publications written about "Ifosfamide" by people in this website by year, and whether "Ifosfamide" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2010 | 0 | 1 | 1 |
| 2017 | 0 | 7 | 7 |
| 2019 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Ifosfamide" by people in Profiles.
-
Treatment of advanced soft tissue sarcoma by histological subtype: wish, prediction or reality? Future Oncol. 2019 Sep; 15(26s):5-10.
-
Outcome of patients with intracranial non-germinomatous germ cell tumors-lessons from the SIOP-CNS-GCT-96 trial. Neuro Oncol. 2017 Nov 29; 19(12):1661-1672.
-
Primary metastatic osteosarcoma: results of a prospective study in children given chemotherapy and interleukin-2. Med Oncol. 2017 Nov 01; 34(12):191.
-
Outcomes in non-metastatic treatment naive extremity osteosarcoma patients treated with a novel non-high dosemethotrexate-based, dose-dense combination chemotherapy regimen 'OGS-12'. Eur J Cancer. 2017 11; 85:49-58.
-
Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. Lancet Oncol. 2017 06; 18(6):812-822.
-
Delayed rhabdomyolysis with paclitaxel, ifosfamide, carboplatin, and etoposide regimen: a case report. J Med Case Rep. 2017 Apr 11; 11(1):100.
-
Bilateral sciatic nerve neurolymphomatosis: PET/CT findings. Ann Hematol. 2017 Jun; 96(6):1059-1060.
-
Abdominal desmoplastic small round cell tumor without extraperitoneal metastases: Is there a benefit for HIPEC after macroscopically complete cytoreductive surgery? PLoS One. 2017; 12(2):e0171639.
-
Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. Lancet Oncol. 2010 Jun; 11(6):561-70.